UK-based NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced the appointment of Michael Shih as chief executive (CEO) and to the board of directors, effective immediately. 16 December 2024
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief medical officer (CMO) and will become a member of Gilead’s senior leadership team. Dr Berger succeeds Dr Merdad Parsey. 13 December 2024
AstraZeneca has brought in Iskra Reic to replace Leon Wang, who is on extended leave from the Anglo-Swedish drugmaker while under investigation in China. 4 December 2024
Bausch Health Bausch Health (NYSE/TSX: BHC) has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. 3 December 2024
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Specialist pre-clinical contract research organization (CRO) and ion channel screening company Metrion Biosciences has announced the appointment of Lee Patterson as its new chief executive. 25 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
Novartis’ Vas Narasimhan, who became chief executive of the company on February 1, has now found a replacement for his previous post as head of global drug development (GDD) and chief medical officer, naming John Tsai to the position. 19 April 2018
GlaxoSmithKline today revealed is has appointed Kevin Sin as senior vice president and head of worldwide business development for pharmaceuticals research and development. 18 April 2018
Menarini, one of Italy’s largest pharma companies and still headed by the founding Aleotti family, has decided to entrust the chairmanship of the company to an external manager coming from a large multinational, Dr Eric Cornut. 29 March 2018
After 19 years with the US healthcare giant Johnson & Johnson (NYSE: JNJ), Dominic Caruso, executive vice president, chief financial officer, has elected to retire in September 2018. 22 March 2018
Christine Roy-Duval has left her role as international clinical investigation director at French pharma major Sanofi’s diabetes unit to join metabolic diseases specialist Valbiotis. 21 March 2018
A year after relinquishing the leadership of the UK’s leading drugmaker, Sir Andrew Witty has been named chief executive of a fast-growing player in the pharmacy benefit manager (PBM) space. 14 March 2018
The departure of André Wyss, president of Novartis Operations, has prompted a series of structural and personnel changes at the top of the Swiss pharma major. 12 March 2018
Swiss pharma giant Roche today announced that Dr John Reed head of Roche Pharma Research and Early Development (pRED) since 2013, has decided to leave Roche for personal reasons and will return to the USA effective April 2, 2018. 9 March 2018
James Kehoe, chief financial officer (CFO) of Takeda, is leaving his role with the Japanese pharma company to become global CFO of Walgreens Boots Alliance. 8 March 2018
The head of Japanese pharma major Astellas’ (TYO: 4503) US operations is moving to take up a top position at US CNS focussed drugmaker Alkermes (Nasdaq: ALKS). 1 March 2018
Ahead of next month’s annual general meeting, Danish diabetes giant Novo Nordisk has confirmed the recommendation that Helge Lund be named the new chairman of the board of directors. 23 February 2018
As the US Centers for Disease Control and Prevention (CDC) struggles to manage the country’s worst flu outbreak in years, the agency suffered a blow Wednesday with the resignation of its director Brenda Fitzgerald. 2 February 2018
Danish diabetes giant Novo Nordisk took a 6% hit in the stock market on Thursday morning after announcing results from the fourth quarter of 2017 along with the full-year figures. 1 February 2018
A long-standing leader in health technology assessment (HTA) in the UK and internationally has taken a step across the divide to become a leading lobbyist for pharma. 25 January 2018